Abstract:Topoisomerase II (TOP2) poisons are effective cytotoxic anticancer agents that stabilize the normally transient TOP2-DNA covalent complexes formed during the enzyme reaction cycle. These drugs include etoposide, mitoxantrone, and the anthracyclines doxorubicin and epirubicin. Anthracyclines also exert cell-killing activity via TOP2-independent mechanisms, including DNA adduct formation, redox activity, and lipid peroxidation. Here, we show that anthracyclines and another intercalating TOP2 poison, mitoxantrone, stabilize TOP2-DNA covalent complexes less efficiently than etoposide, and at higher concentrations they suppress the formation of TOP2-DNA covalent complexes, thus behaving as TOP2 poisons at low concentration and inhibitors at high concentration. We used induced pluripotent stem cell (iPSC)-derived human cardiomyocytes as a model to study anthracycline-induced damage in cardiac cells. Using immunofluorescence, our study is the first to demonstrate the presence of topoisomerase IIβ (TOP2B) as the only TOP2 isoform in iPSC-derived cardiomyocytes. In these cells, etoposide robustly induced TOP2B covalent complexes, but we could not detect doxorubicin-induced TOP2-DNA complexes, and doxorubicin suppressed etoposide-induced TOP2-DNA complexes. In vitro, etoposide-stabilized DNA cleavage was attenuated by doxorubicin, epirubicin, or mitoxantrone. Clinical use of anthracyclines is associated with cardiotoxicity. The observations in this study have potentially important clinical consequences regarding the effectiveness of anticancer treatment regimens when TOP2-targeting drugs are used in combination. These observations suggest that inhibition of TOP2B activity, rather than DNA damage resulting from TOP2 poisoning, may play a role in doxorubicin cardiotoxicity. SIGNIFICANCE STATEMENT: We show that anthracyclines and mitoxantrone act as topoisomerase II (TOP2) poisons at low concentration but attenuate TOP2 activity at higher concentration, both in cells and in in vitro cleavage experiments. Inhibition of type II topoisomerases suppresses the action of other drugs that poison TOP2. Thus, combinations containing anthracyclines or mitoxantrone and etoposide may reduce the activity of etoposide as a TOP2 poison and thus reduce the efficacy of drug combinations.

Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II

Random Mutagenesis of the B′A′ Core Domain of Yeast DNA Topoisomerase II and Large-Scale Screens of Mutants Resistant to the Anticancer Drug Etoposide

From the TOP: Formation, Recognition and Resolution of Topoisomerase DNA Protein Crosslinks

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

T-Cell Protein Tyrosine Phosphatase is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide

Design and Synthesis of the Novel DNA Topoisomerase II Inhibitors: Esterification and Amination Substituted 4'-Demethylepipodophyllotoxin Derivates Exhibiting Anti-Tumor Activity by Activating ATM/ATR Signaling Pathways.

Attenuation of Drug-Stimulated Topoisomerase Ii Dna Cleavable Complex Formation in Wild-Type Hl-60 Cells Treated with an Intracellular Calcium Buffer is Correlated with Decreased Cytotoxicity and Site-Specific Hypophosphorylation of Topoisomerase Ii Alpha

Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging

Brca1 and Brca2 Deficient Cells Are Sensitive to Etoposide-Induced Dna Double Strand Breaks Via Topoisomerase Ii

Mechanism of action of DNA topoisomerase inhibitors

Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity

Circumvention of Topoisomerase II{alpha} Intron 19 Intronic Polyadenylation in Acquired Etoposide-Resistant Human Leukemia K562 Cells

Altered Drug Interaction and Regulation of Topoisomerase IIbeta: Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide.

Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents

Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.

Inhibition of topoisomerase 2 catalytic activity impacts the integrity of heterochromatin and repetitive DNA and leads to interlinks between clustered repeats

Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway

Etoposide-induced DNA Damage Affects Multiple Cellular Pathways in Addition to DNA Damage Response.

Modeling Allosteric Mechanisms of Eukaryotic Type II Topoisomerases